• Target：
• Ob-R

• Fields：
• >>Cytokine-cytokine receptor interaction;>>Neuroactive ligand-receptor interaction;>>AMPK signaling pathway;>>JAK-STAT signaling pathway;>>Adipocytokine signaling pathway;>>Non-alcoholic fatty liver disease

• Gene Name：
• LEPR DB OBR

• Protein Name：
• Leptin receptor (LEP-R) (HuB219) (OB receptor) (OB-R) (CD antigen CD295)

• Sequence：
• P48357

• Human Gene Id：
• 3953

• Human Swiss Prot No：
• P48357

• Mouse Gene Id：
• 16847

• Mouse Swiss Prot No：
• P48356

• Rat Gene Id：
• 24536

• Rat Swiss Prot No：
• Q62959

• Immunogen：
• Synthesized peptide derived from human Leptin Receptor (Phospho Tyr986)

• Specificity：
• This antibody detects endogenous levels of Leptin Receptor (Phospho Tyr986) Rabbit pAb at Human, Mouse,Rat

• Formulation：
• Liquid in PBS containing 50% glycerol, and 0.02% sodium azide.

• Source：
• Rabbit,polyclonal

• Dilution：
• WB 1:500-2000 IHC 1:50-200

• Purification：
• The antibody was affinity-purified from rabbit serum by affinity-chromatography using specific immunogen.

• Concentration：
• 1 mg/ml

• Storage Stability：
• -15°C to -25°C/1 year(Do not lower than -25°C)

• Other Name：
• Leptin receptor (LEP-R) (HuB219) (OB receptor) (OB-R) (CD antigen CD295)

• Observed Band(KD)：
• 132kD

• Background：
• leptin receptor(LEPR) Homo sapiens The protein encoded by this gene belongs to the gp130 family of cytokine receptors that are known to stimulate gene transcription via activation of cytosolic STAT proteins. This protein is a receptor for leptin (an adipocyte-specific hormone that regulates body weight), and is involved in the regulation of fat metabolism, as well as in a novel hematopoietic pathway that is required for normal lymphopoiesis. Mutations in this gene have been associated with obesity and pituitary dysfunction. Alternatively spliced transcript variants encoding different isoforms have been described for this gene. It is noteworthy that this gene and LEPROT gene (GeneID:54741) share the same promoter and the first 2 exons, however, encode distinct proteins (PMID:9207021).[provided by RefSeq, Nov 2010],

• Function：
• domain:The box 1 motif is required for JAK interaction and/or activation.,domain:The cytoplasmic domain may be essential for intracellular signal transduction by activation of JAK tyrosine kinase and STATs.,domain:The WSXWS motif appears to be necessary for proper protein folding and thereby efficient intracellular transport and cell-surface receptor binding.,function:Receptor for obesity factor (leptin). On ligand binding, mediates signaling through JAK2/STAT3. Involved in the regulation of fat metabolism and, in a hematopoietic pathway, required for normal lymphopoiesis. May play a role in reproduction. Can also mediate the ERK/FOS signaling pathway.,PTM:On ligand binding, phosphorylated on two conserved C-terminal tyrosine residues (isoform B only) by JAK2. Tyr-986 is required for complete binding and activation of PTPN11, ERK/FOS activation and, for interaction with SOCS3 (By similar

• Subcellular Location：
• Cell membrane ; Single-pass type I membrane protein . Basolateral cell membrane .; [Isoform E]: Secreted .

• Expression：
• Isoform A is expressed in fetal liver and in hematopoietic tissues and choroid plexus. In adults highest expression in heart, liver, small intestine, prostate and ovary. Low level in lung and kidney. Isoform B is highly expressed in hypothalamus, but also in skeletal muscle. Detected in fundic and antral epithelial cells of the gastric mucosa (PubMed:19159218). Isoform B and isoform A are expressed by NK cells (at protein level) (PubMed:12504075).

• June 19-2018
• WESTERN IMMUNOBLOTTING PROTOCOL

• June 19-2018
• IMMUNOHISTOCHEMISTRY-PARAFFIN PROTOCOL

• June 19-2018
• IMMUNOFLUORESCENCE PROTOCOL

• September 08-2020
• FLOW-CYTOMEYRT-PROTOCOL

• May 20-2022
• Cell-Based ELISA│解您多样本WB检测之困扰

• July 13-2018
• CELL-BASED-ELISA-PROTOCOL-FOR-ACETYL-PROTEIN

• July 13-2018
• CELL-BASED-ELISA-PROTOCOL-FOR-PHOSPHO-PROTEIN

• July 13-2018
• CELL-BASED-COLORIMETRIC-ELISA-PROTOCOL-FOR-TOTAL-PROTEIN

• July 13-2018
• Antibody-FAQs